Human papillomavirus transmission and cost-effectiveness of introducing quadrivalent HPV vaccination in Denmark

International Journal of Technology Assessment in Health Care

Volumn 26, Issue 2, 2010, Pages 183-191

  Olsen, Jens ^a   Jepsen, Martin Rudbeck ^b  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b NATIONAL ENVIRONMENTAL RESEARCH INSTITUTE   (Denmark)

Author keywords

Cervical cancer; Cost effectiveness; Genital warts; HPV transmission; HPV vaccination

Indexed keywords

AGENT BASED; BEFORE AND AFTER; CERVICAL CANCER; CERVICAL CANCERS; CERVICAL INTRAEPITHELIAL NEOPLASIAS; COST-EFFECTIVENESS RATIOS; DENMARK; DISCOUNT RATES; HUMAN PAPILLOMAVIRUS; INCREMENTAL COST; MODEL SIMULATION; QUALITY OF LIFE; TIME HORIZONS; TRANSMISSION MODEL; TREATMENT COSTS; TWO PHASIS;

COMPUTER SIMULATION; COST EFFECTIVENESS; COSTS;

COST BENEFIT ANALYSIS;

WART VIRUS VACCINE;

ARTICLE; CHILD; CONDYLOMA ACUMINATUM; COST EFFECTIVENESS ANALYSIS; DENMARK; FEMALE; HEALTH CARE COST; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SURVIVAL; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VIRUS TRANSMISSION; WART VIRUS;

ADULT; AGED; AGED, 80 AND OVER; ALPHAPAPILLOMAVIRUS; DENMARK; FEMALE; HUMANS; IMMUNIZATION PROGRAMS; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; YOUNG ADULT;

EID: 77953554172     PISSN: 02664623     EISSN: 14716348     Source Type: Journal    
DOI: 10.1017/S0266462310000085     Document Type: Article

References (25)

1. Bergeron C, Largeron N, McAllister R, Mathevet P, Remy V. Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France. Int J Technol Assess Health Care. 2008;24:10-19. (Pubitemid 351158538)
2. Burchell AN, Richardson H, Mahmud SM, et al. Modeling the sexual transmissibility of human papillomavirus infection using stochastic computer simulation and empirical data from a cohort study of young women in Montreal, Canada. Am J Epidemiol. 2006;163:534-543.
3. Canadian Agency forDrugs and Technologies in Health. Guidelines for the economic evaluation of health technologies: Canada. 3rd ed. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2006.
4. Clifford GM, Rana RK, Franceschi S, et al. Human papillomavirus genotype distribution in low-grade cervical lesions: Comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev. 2005;14:1157-1164.
5. Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis. 2007;13:28-41.
6. European Medicines Agency. Gardasil-H-C-703-II-06. Annex
7. Summary of Product Characteristics. London: European Medicines Agency; 2008.
8. Hu D, Goldie S. The economic burden of noncervical human papillomavirus disease in the United States. Am J Obstet Gynecol. 2008;198:500-507.
9. Jakobsen AK, Engelholm SA, Knudsen JB. [Cervix cancer]. Ugeskr Laeger. 2002;164:3059-3062.
10. Jit M, Choi YH, Edmunds WJ. Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ. 2008;337:a769.
11. Kim SY, Goldie SJ. Cost-effectiveness analyses of vaccination programmes: A focused review of modelling approaches. Pharmacoeconomics. 2008;26:191-215.
12. Kjaer SK, Tran TN, Sparen P, et al. The burden of genital warts: A study of nearly 70,000 women from the general female population in the 4 Nordic countries. J Infect Dis. 2007;196:1447-1454.
13. Lacey CJ, Lowndes CM, Shah KV. Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine. 2006;24(Suppl 3):S35-S41.
14. Langley PC, Langley-Hawthorne C, Rash R. Data on file report. A retrospective analysis of treatment patterns and costs in external genital warts in Danish dermatology clinics. 3M Pharmaceuticals; 2001.
15. Langley PC, Langley-Hawthorne C, Rash R. Study report.Aretrospective analysis of treatment patterns and costs of external genital warts in general practice in Denmark. 3M Pharmaceuticals; 2001.
16. Ministry of Health and Prevention [Ministeriet for Sundhed og Forebyggelse]. Agreement between the government (Liberal and Conservative parties), Danish People's Party, Social-Liberal Party and New Alliance about: New initiatives in the health care sector (1st March 2008 [Aftale mellem regeringen (Venstre og Konservative), Dansk Folkeparti, Det Radikale Venstre ogNyAlliance om: Nye initiativer p°a sundhedsomr°adet (1. marts 2008)]. Denmark: Ministry of Health and Prevention; 2008.
17. Monsonego J, Breugelmans JG, Bouee S, et al. [Anogenital warts incidence, medical management and costs in women consulting gynaecologists in France]. Gynecol Obstet Fertil. 2007;35:107-113.
18. National Board of Health. Liquid-based cytology and conventional Pap smear used in cervical cancer screening in Denmark - a health technology assessment [Væskebaseret teknik og udstryningsteknik anvendt til screening for livmoderhalskræft i Danmark-en medicinsk teknologivurdering]. Copenhagen: National Board of Health; 2005.
19. National Board of Health. Reduction in the risk of cervical cancer by vaccination against human papillomavirus (HPV) - a health technology assessment. Copenhagen: National Board of Health, Danish Centre for Health Technology Assessment; January 20, 2007. Report No: 9(1).
20. National Board of Health. The cancer registry and the causes of death registry. Copenhagen: National Board of Health; 2008.
21. Olsson SE, Villa LL, Costa RL, et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine. 2007;25:4931-4939.
22. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.
23. Smith JS, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: A meta-analysis update. Int J Cancer. 2007;121:621-632.
24. The UK Collaborative Group for HIV and STI Surveillance. Testing times. HIV and other sexually transmitted infections in the United Kingdom: 2007. London: Health Protection Agency, Centre for Infections; November 2007.
25. Usher C, Tilson L, Olsen J, et al. Cost-effectiveness of human papillomavirus vaccine in reducing the risk of cervical cancer in Ireland due to HPV types 16 and 18 using a transmission dynamic model. Vaccine. 2008;26:5654-5661.